137 related articles for article (PubMed ID: 37682791)
21. Lenalidomide plus rituximab (R
Becnel MR; Nastoupil LJ; Samaniego F; Davis RE; You MJ; Green M; Hagemeister FB; Fanale MA; Fayad LE; Westin JR; Wang M; Oki Y; Forbes SG; Feng L; Neelapu SS; Fowler NH
Br J Haematol; 2019 Jun; 185(5):874-882. PubMed ID: 30919940
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Lamm W; Kaufmann H; Raderer M; Hoffmann M; Chott A; Zielinski C; Drach J
Haematologica; 2011 Jul; 96(7):1008-14. PubMed ID: 21486866
[TBL] [Abstract][Full Text] [Related]
24. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
25. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Leonard JP; Jung SH; Johnson J; Pitcher BN; Bartlett NL; Blum KA; Czuczman M; Giguere JK; Cheson BD
J Clin Oncol; 2015 Nov; 33(31):3635-40. PubMed ID: 26304886
[TBL] [Abstract][Full Text] [Related]
26. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
[TBL] [Abstract][Full Text] [Related]
27. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
28. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW; Edwin N; Redd R; Bsat J; Chase M; LaCasce A; Freedman A; Jacobson C; Fisher D; Ng S; Crombie J; Kim A; Odejide O; Davids MS; Brown JR; Jacene H; Cashen A; Bartlett NL; Mehta-Shah N; Ghobadi A; Kahl B; Joyce R; Armand P; Jacobsen E
Blood Adv; 2020 Mar; 4(5):858-867. PubMed ID: 32126141
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A; Steurer M; Melchardt T; Weiss L; Gassner FJ; Zaborsky N; Geisberger R; Catakovic K; Hartmann TN; Pleyer L; Voskova D; Thaler J; Lang A; Girschikofsky M; Petzer A; Greil R
Ann Hematol; 2018 Oct; 97(10):1825-1839. PubMed ID: 29862437
[TBL] [Abstract][Full Text] [Related]
30. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
[TBL] [Abstract][Full Text] [Related]
31. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Gressin R; Daguindau N; Tempescul A; Moreau A; Carras S; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Pignon JM; Corm S; Banos A; Mounier C; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouadallah K; Amorin S; Garidi R; Voillat L; Joly B; Celigny PS; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Le Gouill S; Callanan MB;
Haematologica; 2019 Jan; 104(1):138-146. PubMed ID: 30171024
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
Ruan J; Shah B; Martin P; Schuster SJ
Ann Oncol; 2016 Jul; 27(7):1226-34. PubMed ID: 27052651
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
34. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
35. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
38. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R
Morschhauser F; Nastoupil L; Feugier P; Schiano de Colella JM; Tilly H; Palomba ML; Bachy E; Fruchart C; Libby EN; Casasnovas RO; Flinn IW; Haioun C; Maisonneuve H; Ysebaert L; Bartlett NL; Bouabdallah K; Brice P; Ribrag V; Le Gouill S; Daguindau N; Guidez S; Pica GM; García-Sancho AM; López-Guillermo A; Larouche JF; Ando K; Gomes da Silva M; André M; Kalung W; Sehn LH; Izutsu K; Cartron G; Gkasiamis A; Crowe R; Xerri L; Fowler NH; Salles G
J Clin Oncol; 2022 Oct; 40(28):3239-3245. PubMed ID: 35947804
[No Abstract] [Full Text] [Related]
39. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
[TBL] [Abstract][Full Text] [Related]
40. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
